Routine annual meeting with equity plan refresh — expect minimal stock price reaction. The equity plan provides additional compensation runway for a clinical-stage biotech, but does not signal any near-term catalyst or change in fundamentals. Monitor upcoming pipeline data readouts for actual stock-moving events.
Price Chart
Executive Summary
Tenaya Therapeutics held its 2026 annual meeting on May 27, 2026, where shareholders approved an amended and restated 2021 Equity Incentive Plan. The plan was amended to add a one-time increase of 6,509,966 shares (~3% of outstanding), remove the 4 million share annual evergreen cap (keeping the 4% of outstanding formula), and limit incentive stock option shares. The three Class II director nominees (Burroughs, Parschauer, Stehman-Breen) were elected, and Deloitte & Touche LLP was ratified as independent auditor.
Key Facts
- Shareholders approved amended 2021 Equity Incentive Plan with 67,356,607 For (20,575,701 Against, 2,356,444 Abstain, 48,606,132 broker non-votes)
- One-time increase of 6,509,966 shares reserved under the plan (~3% of outstanding)
- Annual evergreen provision amended: removes 4M share cap, maintains 4% of outstanding shares formula
- Maximum incentive stock option shares limited to 15,000,000
- Class II directors Amy Burroughs, Karah Parschauer, and Catherine Stehman-Breen each elected with >86M votes For
- Ratification of Deloitte & Touche LLP as independent auditor passed with 135,650,321 For
- No departures, appointments, or compensation changes to officers or directors were reported
Financial Impact
Approval of equity plan adds ~6.5M shares to reserve (~3% dilution potential over time); no immediate earnings or cash impact
Risk Factors
- Potential future dilution as new awards are granted under the expanded plan
- No material operational or financial updates were provided in this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-248680 |
| Document: tnya-20260527.htm | 0001193125-26-248680 |
| Document: 0001193125-26-248680-index-headers.html | 0001193125-26-248680 |
| Document: 0001193125-26-248680-index.html | 0001193125-26-248680 |
| Document: 0001193125-26-248680.txt | 0001193125-26-248680 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 2d ago | DEFA14A | $0.3945 | awaiting T+60 | — | $0.4086 (+3.57%) |
Oct 23, 2026 3d ago | DEF 14A | $0.3850 | awaiting T+60 | — | $0.4086 (−6.13%) |
Aug 17, 2026 9w ago | 144 | $0.6990 | awaiting T+60 | — | $0.4086 (+41.55%) |
Jul 2, 2026 16w ago | 8-K | $0.7869 $0.5898 | ▼ −25.05% | ▼ −28.62% | $0.4086 (−48.07%) |
Jun 29, 2026 17w ago | 8-K | $0.7349 $0.6822 | ▼ −7.17% | ▼ −11.56% | $0.4086 (−44.40%) |
Jun 12, 2026 19w ago | Institutional Cluster | $0.7118 $0.6634 | ▲ +6.80% | ▲ +10.06% | $0.4086 (+42.60%) |
May 29, 2026 21w ago | 8-K | $0.8700 $0.7014 | ▼ −19.38% | ▼ −20.61% | $0.4086 (−53.03%) |
May 19, 2026 22w ago | Insider Cluster | $0.8080 $0.7281 | ▼ −9.89% | ▼ −14.89% | $0.4086 (−49.43%) |
Apr 16, 2026 27w ago | DEFA14A | $0.7470 $0.8365 | ▲ +11.98% | ▲ +4.94% | $0.4086 (−45.30%) |
Mar 11, 2026 32w ago | 8-K | $0.8930 $0.7280 | ▼ −18.48% | ▼ −29.17% | $0.4086 (−54.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers